product approval introduction

Ipsen Receives Positive Opinion In Europe for Dysport® In the Management of Urinary Incontinence In Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury

Share

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who are regularly performing clean intermittent catheterization (CIC).  This positive opinion for Dysport® now permits individual European country Health Authorities to grant national approvals, according to their country regulations.  In addition, Ipsen is also currently in the process of obtaining approvals in other countries outside the European Union. Read more.

Source: Globe Newswire, June 9, 2022

Posted in News and tagged , , , , , , , , .